Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 4. RPL22L1 expression was associated with immune infiltration, immune score, and immune checkpoint genes in LUAD. (A) Lollipop plot. (B) Grouped comparison plots. (C) Check point genes. Statistical significance was denoted by asterisks, with *, **, and *** representing p-values less than 0.05, 0.01, and 0.001, respectively.